Vyome Holdings, Inc.
HINDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Vyome Holdings, Inc. focuses on Biotechnology services and products. Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. With a market capitalization of $12.6M, it sits in micro-cap territory. It operates through Pharmaceutical and Biotechnology segments.
Market Cap
$12.6M
Beta
—
P/E (TTM)
1.01
P/E (Fwd)
—
EPS (TTM)
$1.77
EPS (Fwd)
—
ROE
-999.2%
ROA
-48.8%
Cash
$7.9M
Total Debt
$17,310
Free CF
$3.6M
52W Change
-67.4%
Annual Financials
Cash vs Debt
Where HIND stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, HIND finished 14.02% below its 150-day moving average ($2.14) and 20.35% below its 200-day moving average ($2.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HIND overbought or oversold?
At the October 20, 2026 close, HIND's RSI(14) was 35.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Vyome Holdings, Inc. holds $7.9M in cash against $17K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $3.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -999.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $383K to $320K.
With cash comfortably exceeding debt, HIND has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Vyome Holdings, Inc.'s trajectory.